GP120

GP120 Overview

English NameHIV envelope protein gp120Approved Drugs2
Drugs in Clinical Trials14Target SynonymHIV Envelope Protein gp120
Highest Development StageApproved
English NameHIV envelope protein gp120
Target SynonymHIV Envelope Protein gp120
Approved Drugs2
Drugs in Clinical Trials14
Highest Development StageApproved

Product Inquiry

GP120 Background

Human Immunodeficiency Virus (HIV) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa. HIV-2 is related to viruses found in sooty mangabeys. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Some of the HIV-1 group M subtypes are known to be more virulent or are resistant to different medications. HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses.Envelope glycoprotein GP120 (or gp120) is the name of the glycoprotein which forms the spikes sticking out of a HIV virus particle. gp120 is essential for virus entry into cells as it plays a vital role in seeking out specific cell surface receptors for entry. Three gp120s, bound as heterodimers to a transmembrane glycoprotein, gp41, are thought to combine in a trimer to form the envelope spike, which is involved in virus-cell attachment. One half of the molecular weight of gp120 is due to the carbohydrate side chains (the "glyco-" in "glycoprotein"). These are sugar residues which form something almost like a sugar "dome" over the gp120 spikes. This dome prevents gp120 from being recognised by the human immune response. As the HIV virus and the human CD4 cell come together, the gp120 binding site "snaps open" at the last minute.The glycoprotein gp120 is anchored to the viral membrane, or envelope, via non-covalent bonds with the transmembrane glycoprotein, gp41. It is involved in entry into cells by binding to CD4 receptors, particularly helper T-cells. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

GP120 Synonyms

GP120,GP120-CN54

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Zinlirvimab10-1074; 10-1074-LS; GS-2872Phase 2 ClinicalThe Rockefeller UniversityHIV Infections; Acquired Immunodeficiency Syndrome
Details
PGT121.414.LSVRC-HIVMAB0107-00-ABPhase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
PGT-121PGT-121Phase 2 ClinicalInternational Aids Vaccine Initiative, Theraclone Sciences Inc, The Scripps Research Institute Inc, The Ragon Institute Of Mgh, Mit And HarvardHIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral
Details
Teropavimab3BNC117-LS-J; 3BNC117-LS; 3BNC117; GS-5423Phase 2 ClinicalThe Rockefeller UniversityHIV Infections; Acquired Immunodeficiency Syndrome
Details
Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung)Phase 1 ClinicalPolymun Scientific GmbhHIV Infections
Details
PDPHV-201401PDPHV-201401Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
ElipovimabGS-9722Phase 1 ClinicalGilead IncHIV Infections
Details
VRC-HIVAAV070-00-GTAAV8-VRC07Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
Microbicide Monoclonal Antibody Triple Combination (Polymun)Phase 1 ClinicalHIV Infections
Details
env (A, B, C, A/E)/gag DNA Vaccine(NIAID)PD-201401Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
Vrc-Hivmab0121-00-AbCAP256J3LSPhase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
Details
FB-1002(Frontier Biotechnologies)FB-1002(前沿生物)Phase 1 ClinicalFrontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of SciencesCoronavirus Disease 2019 (COVID-19)
Details
DS-003DS-003; BMS-793Phase 1 ClinicalBristol-Myers Squibb CompanyHIV Infections; Neoplasms
Details
A-1801A-1801ClinicalWuhan BioRaid Biotechnology Co LtdHIV Infections
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Radha-108ApprovedBiomix NetworkReceptolHIV Infections
Details
Fostemsavir TromethamineBMS-663068; 97IQ273H4L (UNII code); GSK 3684934; BMS-663068-03; GSK-3684934A; BMS 626529 prodrugApprovedBristol-Myers Squibb CompanyRukobiaUnited StatesHIV InfectionsViiv Healthcare Co2020-07-02HIV Infections
Details
  • Overview
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland